Literature DB >> 22209868

Lost in disruption: role of proteases in glioma invasion and progression.

Rolf Mentlein1, Kirsten Hattermann, Janka Held-Feindt.   

Abstract

A characteristic feature of malignant glial tumors (gliomas) is their tendency to diffusely infiltrate the nervous system preventing their complete surgical resection. Proteases play a decisive role in this malignant process, either by degradation of brain extracellular matrix (ECM) components, adhesion molecules, or by regulating the activity of growth and chemotactic factors. Secreted matrix metalloproteinases (MMPs) and ADAMTS proteases (ADAMs with thrombospondin motifs) cleave different ECM components like the proteoglycans (lecticans) aggrecan, versican, neurocan and brevican with selective preferences; they are further regulated by endogenous inhibitors and activating metallo- and serine proteases. Cell surface proteases of the ADAM family (A Disintegrin And Metalloproteinase), but also serine proteases regulate the activity of growth factors and chemokines that act as autocrine / paracrine stimulators within gliomas. Thus, proteases play a decisive role for the spread and growth of gliomas and are prominent targets for their therapy. Copyright Â
© 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22209868     DOI: 10.1016/j.bbcan.2011.12.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  27 in total

Review 1.  The role of AEG-1/MTDH/LYRIC in the pathogenesis of central nervous system disease.

Authors:  Evan K Noch; Kamel Khalili
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

2.  ADAM-9 is a novel mediator of tenascin-C-stimulated invasiveness of brain tumor-initiating cells.

Authors:  Susobhan Sarkar; Franz J Zemp; Donna Senger; Stephen M Robbins; V Wee Yong
Journal:  Neuro Oncol       Date:  2015-02-01       Impact factor: 12.300

3.  Loss of SPINT2 expression frequently occurs in glioma, leading to increased growth and invasion via MMP2.

Authors:  Márcia Santos Pereira; Sónia Pires Celeiro; Ângela Margarida Costa; Filipe Pinto; Sergey Popov; Gisele Caravina de Almeida; Júlia Amorim; Manuel Melo Pires; Célia Pinheiro; José Manuel Lopes; Mrinalini Honavar; Paulo Costa; José Pimentel; Chris Jones; Rui Manuel Reis; Marta Viana-Pereira
Journal:  Cell Oncol (Dordr)       Date:  2019-11-07       Impact factor: 6.730

4.  RUNX1 Regulates Migration, Invasion, and Angiogenesis via p38 MAPK Pathway in Human Glioblastoma.

Authors:  Kant Sangpairoj; Pornpun Vivithanaporn; Somjai Apisawetakan; Sukumal Chongthammakun; Prasert Sobhon; Kulathida Chaithirayanon
Journal:  Cell Mol Neurobiol       Date:  2016-12-24       Impact factor: 5.046

5.  The Combined Influence of Hydrogel Stiffness and Matrix-Bound Hyaluronic Acid Content on Glioblastoma Invasion.

Authors:  Jee-Wei Emily Chen; Sara Pedron; Brendan A C Harley
Journal:  Macromol Biosci       Date:  2017-04-05       Impact factor: 4.979

Review 6.  Role of tenascins in the ECM of gliomas.

Authors:  Nicole Brösicke; Andreas Faissner
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

Review 7.  Meningiomas and Proteomics: Focus on New Potential Biomarkers and Molecular Pathways.

Authors:  Rosaria Viola Abbritti; Francesca Polito; Maria Cucinotta; Claudio Lo Giudice; Maria Caffo; Chiara Tomasello; Antonino Germanò; Mohammed Aguennouz
Journal:  Cancer Genomics Proteomics       Date:  2016 09-10       Impact factor: 4.069

Review 8.  A neurocentric perspective on glioma invasion.

Authors:  Vishnu Anand Cuddapah; Stefanie Robel; Stacey Watkins; Harald Sontheimer
Journal:  Nat Rev Neurosci       Date:  2014-07       Impact factor: 34.870

9.  Dihydroartemisinin suppresses glioma proliferation and invasion via inhibition of the ADAM17 pathway.

Authors:  Junyan Chen; Xiangrong Chen; Fan Wang; Hongzhi Gao; Weipeng Hu
Journal:  Neurol Sci       Date:  2014-10-10       Impact factor: 3.307

10.  ProBDNF and its receptors are upregulated in glioma and inhibit the growth of glioma cells in vitro.

Authors:  Jing Xiong; Li Zhou; Miao Yang; Yoon Lim; Yu-hong Zhu; Deng-li Fu; Zhi-wei Li; Jin-hua Zhong; Zhi-cheng Xiao; Xin-Fu Zhou
Journal:  Neuro Oncol       Date:  2013-04-10       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.